Roche appointed Pascal Soriot to chief operating officer of its pharmaceutical division, replacing William Burns, who will become a member of the company’s board, according to a statement. Soriot was appointed to CEO at Roche-acquired Genentech earlier this year. Additionally, Roche tapped Daniel O’Day as chief operating officer of its diagnostic division, replacing Juergen Schwiezer, who is scheduled to retire at the end of the year. Ian Clark will step in as head of Genentech, replacing Soriot.
Waterfront Media announced the appointment of Aaron Tobin as senior director of strategy for Everyday Health. Tobin will serve as digital health strategist, specializing in pharma and medical devices, and will work closely with content and sales teams, according to a statement. Tobin was most recently senior account director at Razorfish.
The Lannett Company, a generic pharmaceuticals manufacturer, announced the appointment of Stephen Kovary as vice president of operations, succeeding Bernard Sandiford, who retired. Kovary will report to Arthur Bedrosian, president and CEO. Most recently, Kovary served as VP, plant manager at PF Laboratories, a division of Purdue Pharma, before that he was director of manufacturing at Pliva, Inc., and senior director of operations at Abbott Laboratories.
Rib-X Pharmaceuticals, a Connecticut-based company focused on the development and commercialization of novel antibiotics, announced the hiring of Tom Kassberg as chief business officer. Kassberg, who began his career at Bristo-Myers Squibb, will lead the company’s business development activities. Most recently, Krassberg was EVP, corporate development at Proteolix.
New York City-based GENova Biotherapeutics, a biotech focused on novel drug targets that disrupt the advance of life-threatening diseases, appointed John Savin to vice president. Savin will work with CEO Aaron Whiteman to direct business growth by identifying and acquiring potential drug partners, and then subsequently outsourcing them to partners who can successfully usher them through clinical trials and bring them to market, according to a statement. Savin was most recently CEO of Physiomics, a company he founded.
